ERCC1, RRM1 and TUBB3 mRNA expression on the tumor response and overall survival of non-small cell lung cancer treated with platinum-based chemotherapy

Pakistan Journal of Medical Sciences

Volumn 30, Issue 6, 2014, Pages 1403-1408

  Qiao, Hongwei ^a   Huang, Xiaoping ^a   Guo, Hua ^a   Liu, Yan ^a   Yue, Chunyan ^a  

^a XINXIANG CENTRAL HOSPITAL   (China)

Author keywords

ERCC1; mRNA; Non small cell lung cancer; Overall survival; RRM1; TUBB3; Tumor response

Indexed keywords

BETA TUBULIN; CISPLATIN; COMPLEMENTARY DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; MESSENGER RNA; PLATINUM DERIVATIVE; PROTEIN RRM1; PROTEIN TUBB3; RIBONUCLEOTIDE REDUCTASE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; FEMALE; FLUORESCENCE ANALYSIS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN ISOLATION; TREATMENT OUTCOME; TUMOR LOCALIZATION;

EID: 84910119397     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: 10.12669/pjms.306.5768     Document Type: Article

References (29)

1. International Agency for Research on Cancer (2012). Lung Cancer Estimated incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_ sheets_cancer.aspx. Accessed in 2014-5-1.
2. Rinaldi M, Cauchi C, Gridelli C. First line chemotherapy in advanced or metastatic NSCLC. Ann Oncol. 2006;17 Suppl 5:v64-7. doi:10.1093/annonc/mdj953.
3. Bidoli P, Zilembo N, Cortinovis D, Mariani L, Isa L, Aitini E, et al. Randomized phase II three-arm trial with three platinum-based doublets in metastatic non small-cell lung cancer. An Italian Trials in Medical Oncology Study. Ann Oncol. 2007;18(3):461-467. doi:10.1093/annonc/mdl415
4. Vilmar A and Sorensen JB (2009). Excision repair crosscomplementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer. 2009;64(2):131-139. doi: 10.1016/j.lungcan.2008.08.006.
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92-98.
6. Sarries C, Haura EB, Roig B, Taron M, Abad A, Scagliotti G, et al. Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer. Pharmacogenomics. 2002;3(6):763-780. doi:10.1517/14622416.3.6.763
7. Skroński M, Szpechciński A, Chorostowska-Wynimko J. Current methods to detect EGFR gene mutations as predictive factor for targeted therapies in non-small cell lung cancer - is there a “golden standard” in diagnostics? Pneumonol Alergol Pol. 2014; 82 (3): 311-322. doi: 10.1056/ NEJMoa011954
8. Johnson ML, Patel JD. Chemotherapy and targeted therapeutics as maintenance of response in advanced nonsmall cell lung cancer. Semin Oncol. 2014;41(1):93-100. doi:10.5603/PiAP.2014.0036.
9. Gridelli C, Ardizzoni A, Douillard JY, Hanna N, Manegold C, Perrone F, et al. Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer. 2010;68(3):319-331. doi: 10.1016/j.lungcan.2009.11.018.
10. Fisher LA, Bessho M, Bessho T. Processing of a psoralen DNA interstrand cross-link by XPF-ERCC1 complex in vitro. J Biol Chem. 2008;283(3):1275-1281. doi: 10.1074/jbc. M708072200
11. Simon GR, Ismail-Khan R, Bepler G. Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol. 2007;39(7-8):1318-1328. doi: 10.1016/j.biocel.2007.05.006
12. Xian-Jun F, Xiu-Guang Q, Li Z, Hui F, Wan-Ling W, Dong L, Ping-Fa L. ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy. Pak J Med Sci. 2014;30(3):488-492.
13. Wang TB, Zhang NL, Wang SH, Li HY, Chen SW, Zheng YG. Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy. Genet Mol Res. 2014;13(2):3704-3710.
14. Muallem MZ, Braicu I, Nassir M, Richter R, Sehouli J, Arsenic R. ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer. Anticancer Res. 2014;34(1):393-399.
15. Li W, Jie Z, Li Z, Liu Y, Gan Q, Mao Y, Wang X. ERCC1 siRNA ameliorates drug resistance to cisplatin in gastric carcinoma cell lines. Mol Med Rep. 2014;9(6):2423-2428. doi:10.3892/mmr.2014.2112.
16. Muallem MZ, Marnitz S, Richter R, Köhler C, Sehouli J, Arsenic R. ERCC1 expression as a predictive marker of cervical cancer treated with cisplatin-based chemoradiation. Anticancer Res. 2014;34(1):401-406.
17. Ozdemir O, Ozdemir P, Veral A, Uluer H, Ozhan MH. ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy. Asian Pac J Cancer Prev. 2013;14(8):4679-4683. doi: 10.7314/ APJCP.2013.14.8.4679
18. Qin X, Yao W, Li W, Feng X, Huo X, Yang S, et al. ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinumbased chemotherapy. Tumour Biol. 2014;35(5):4697-4704. doi: 10.1007/s13277-014-1615-8.
19. Zhang Y, Yang H, Qiu Y, Deng Q, Liu J, Zhao M, et al. Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer. Med Oncol. 2014;31(3):803. doi: 10.1007/s12032-013-0803-5.
20. Schneider JG, Farhadfar N, Sivapiragasam A, Geller M, Islam S, Selbs E. Commercial laboratory testing of excision repair cross-complementation group 1 expression in nonsmall cell lung cancer. Oncologist. 2014;19(5):459-465. doi: 10.1634/theoncologist.2013-0311.
21. Yu D, Li J, Han Y, Liu S, Xiao N, Li Y, et al. Gene expression profiles of ERCC1, TYMS, RRM1, TUBB3 and EGFR in tumor tissue from non-small cell lung cancer patients. Chin Med J (Engl). 2014;127(8):1464-1468. doi: 10.3760/ cma.j.issn.0366-6999.20132949
22. Wang TB, Zhang NL, Wang SH, Li HY, Chen SW, Zheng YG. Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy. Genet Mol Res. 2014;13(2):3704-3710. doi:10.4238/2014.May.9.15.
23. Lee HW, Choi YW, Han JH, Kim JH, Jung JH, Jeong SH, et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced nonsmall cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung Cancer. 2009;65(3):377-382. doi: 10.1016/j.lungcan.2008.12.005.
24. Tantraworasin A, Saeteng S, Lertprasertsuke N, Arayawudhikul N, Kasemsarn C, Patumanond J. The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival. Cancer Manag Res. 2013;5:327-336. doi: 10.2147/CMAR.S52073.
25. Han Y, Wang X., Xiao N, Liu ZD. mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in postoperative patients with non-small cell lung cancer. Asian Pac J Cancer Prev. 2013;14(5):2987-2990. doi:10.7314/APJCP.2013.14.5.2987
26. Yang YL, Luo XP, Xian L. The prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis. PLoS One. 2014;9(4):e93997. doi: 10.1371/ journal.pone.0093997.
27. Wang L, Meng L, Wang X., Ma GY, Chen JH. Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy. Tumour Biol. 2014;35(3):1899-1906. doi: 10.1007/s13277-013-1255-4.
28. Bergot E, Levallet G, Campbell K, Dubois F, Lechapt E, Zalcman G. Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy. Eur Respir Rev. 2013;22(130):565-576. doi: 10.1183/09059180.00007113.
29. Jian-Wei B, Yi-Min M, Yu-Xia S, Shi-Qing L. Expression levels of ERCC1 and RRM1 mRNA and clinical outcome of advanced non-small cell lung cancer. Pak J Med Sci. 2013;29(5):1158-1161. doi: 10.12669/pjms.295.3812